Share on StockTwits

AstraZeneca plc (NYSE:AZN)‘s stock had its “buy” rating reiterated by equities researchers at Citigroup Inc. in a research report issued on Friday.

AstraZeneca plc (NYSE:AZN) traded down 0.88% during mid-day trading on Friday, hitting $75.64. The stock had a trading volume of 1,016,258 shares. AstraZeneca plc has a 52 week low of $47.76 and a 52 week high of $82.68. The stock has a 50-day moving average of $73. and a 200-day moving average of $67.87. The company has a market cap of $95.382 billion and a price-to-earnings ratio of 46.79.

AstraZeneca plc (NYSE:AZN) last issued its quarterly earnings data on Thursday, April 24th. The company reported $1.17 earnings per share for the quarter, missing the analysts’ consensus estimate of $1.23 by $0.06. The company had revenue of $6.42 billion for the quarter, compared to the consensus estimate of $6.32 billion. During the same quarter last year, the company posted $1.41 earnings per share. AstraZeneca plc’s revenue was up .5% compared to the same quarter last year. Analysts expect that AstraZeneca plc will post $4.23 EPS for the current fiscal year.

Other equities research analysts have also recently issued reports about the stock. Analysts at JPMorgan Chase & Co. initiated coverage on shares of AstraZeneca plc in a research note on Thursday. They set an “underweight” rating on the stock. Separately, analysts at Deutsche Bank reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Wednesday. Finally, analysts at Liberum Capital reiterated a “buy” rating on shares of AstraZeneca plc in a research note on Friday, June 20th. Four research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and five have assigned a buy rating to the stock. AstraZeneca plc presently has a consensus rating of “Hold” and a consensus price target of $58.67.

AstraZeneca PLC (NYSE:AZN) is a global biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.